Solving unmet needs in transformative new modalities
We help pharmaceutical companies address formulation and delivery challenges in transformative new modalities, including cell and gene therapies.
ViSync is a joint venture that leverages Hovione’s and iBET’s expertise and knowledge to provide technology platform solutions and services to pharmaceutical and biotech companies
Hovione is a science-based company with over 60 years of experience, providing products and integrated services for the Pharmaceutical Industry.
Hovione
The specialist integrated CDMO
Hovione is a Contract Development and Manufacturing Company (CDMO) dedicated to helping Pharmaceutical Customers bring new and off-patent drugs to market. As a CDMO it has a fully integrated offering of services for drug substances, drug product intermediates and drug products.
A private non-profit institution of public utility dedicated to R&D in Biotechnology.
iBET
We create value for our partners leveraging scientific and technological knowledge in biology and chemistry.
For over 35 years, we have been creating and transferring knowledge to our global biopharma and biotech partners and to the national pharma and agri-food industry sector.
What we deliver
We develop technology platforms that help customers bring transformative therapies to patients worldwide.
Nasal and Lung Delivery Innovation
Focusing on nasal and pulmonary delivery through advanced particle engineering, enabling precise formulation of next-generation modalities.
Stability Enhancement for New Therapeutics
Transforming the stability profile of vaccines and gene therapy products, by leveraging particle engineering to create novel formulations that optimize delivery and shelf-life.
Innovative & Scalable Technologies
Driving R&D excellence with scalable particle engineering platforms and development of integrated analytical methods, ensuring robust support across the full spectrum of therapeutic innovation.
Our strengths
ViSync is a research, pre-clinical development company, in the field of Viral and Cell ATMPs, aiming to develop technological platforms to solve current challenges in the fields of stability, targeting and delivery of these therapies.
Knowledge
Extensive knowledge in Gene and Cell therapies combined with Particle Engineering and Formulation development.
Customer Focus
Our team is committed to understanding your needs and exceeding your expectations, delivering your project from end to end.
Flexibility
We are keen to incorporate novel technologies and analytical methods to ensure optimal solutions.
Industry mindset
All solutions are developed with industrial applicability and scaleability in mind.
Challenges
Pharma industry is facing challenges to address previously untreatable diseases. We are here to help.
Formulation challenges
As the therapeutic landscape and treatment modalities evolve, drug delivery strategies must adapt quickly to reflect the changing mode of action and the complexity of therapies.
Manufacturing challenges
Developing and partnering IP-protected platforms, targeted to specific modalities and/or specific targets, is essential to significantly accelerate and de-risk the delivery of new modalities.
Stability and delivery challenges
The stabilization of complex drug delivery systems, such as Viral and non-Viral vectors and more widely new modalities drug delivery systems, is critical to lead to room-temperature supply chain and increase global healthcare accessibility.
So, what is your challenge?
Our team is confident and eager to explore the innovative solutions we can create together. We're committed to providing unwavering support throughout the process. Let’s discuss your specific needs and how we can partner to drive innovation forward.
Roadmap
Our journey towards novel delivery solutions
for emerging therapeutic modalities
Q2 – Q4 • 2024
Setup
Setup equipment, operational team and procedures
Q1 • 2025
Start Operations
R&D operations at a laboratory scale
2027
GMP Facility
Upscale to GMP capabilities
ViSync team
Elsa Abranches
Chief Scientific OfficerElsa Abranches holds a degree in Chemical Engineering and a Ph.D. in Stem Cell Biotechnology, from the Technical University of Lisbon, Portugal.
Elsa has over 20 years of experience in stem cell biotechnology, standardization and Advanced Therapies regulation areas, ranging from applied research through to manufacturing and regulatory compliance of stem cell-derived products. She has held roles at AstraZeneca and at the UK Medicines and Healthcare products Regulatory Agency (MHRA). She has also contributed to numerous collaborative projects with academia, industry and regulatory bodies and has served on several national and international committees supporting regulatory compliance in Advanced Therapy Medicinal Products (ATMPs).
Currently, Elsa is Chief Scientific Officer at ViSync Technologies and the regional treasurer of the European Committee of the International Society for Cell & Gene Therapy (ISCT).
Christoph Bruecher
Board MemberChristoph Bruecher holds a diploma in Organic Chemistry from Free University of Berlin and a Ph.D. in Organic Chemistry from University of Frankfurt, Germany.
He has over 25 years of experience in the pharmaceutical, biopharmaceutical and chemical industry, with management and leadership roles in research & development, business development, alliance management, and intellectual property and contract management in companies such as Hoechst, Aventis, Biotest and Evonik.
Currently, Christoph is VP Business Transformation & Licensing at Hovione.
Manuel Carrondo
Board MemberManuel Carrondo is iBET’s Founder and current Vice-President for Business Development and was formerly a Full Professor of Chemical and Biochemical Engineering at NOVA University of Lisbon.
He has extensive management experience in the biotechnology sector, focusing on Animal Cell Technology, recombinant proteins, virus-like particles, cell therapies, and cGMP scale-up. Manuel was one of the founders of Genibet, a visiting Professor of MIT (USA) and has been an Advisory Board Member for several organizations.
He has published over 250 papers and supervised 35 PhD students. In 2021, he received the Cell Culture Engineering Award and in 2024, the FCT Medal of Scientific Merit.
Teresa Alves
Board MemberTeresa Alves holds a BSc in Biochemistry from Imperial College of Science and Technology in London, a Ph.D. in Molecular Biology from the Institute of Genetics, University of Glasgow, as well as an M.B.A. from Universidade Católica Portuguesa in Lisbon.
She has over 35 years of experience in the pharmaceutical and biopharmaceutical industries, with leadership roles in several companies such as GenIbet, Cipan, and Laboratórios Atral. Teresa has also taught Biochemistry and Industrial Microbiology at Universidade Católica Portuguesa for several years.
Currently, Teresa is Senior Director, Strategic Alliances at Hovione.
Márcio Temtem
Scientific AdvisorMárcio Temtem holds a Ph.D. and a degree in Chemical Engineering from the New University of Lisbon.
With over 15 years of experience in the Pharmaceutical Industry, Márcio has developed extensive expertise in R&D and business-focused areas such as bioavailability enhancement, respiratory drug delivery, and drug product development and manufacturing processes (e.g., tableting, capsule filling, continuous tableting, etc.). Passionate about leadership, Márcio has held several senior roles throughout his career, managing large teams of over 150 people, as well as operating in matrix organizational structures.
Over the past five years, Márcio has reported directly to Hovione’s Executive Team, where he has been responsible for P&L oversight and driving company strategy at both business and corporate levels. Currently, Márcio is VP for Strategic Business Management at Hovione.
Paula Alves
Scientific AdvisorPaula M. Alves is the CEO of iBET and a Professor at NOVA University of Lisbon. She holds a B.Sc. in Biochemistry from the University of Lisbon and a Ph.D. in Biochemical Engineering from NOVA University of Lisbon.
Paula has over 30 years of experience in Animal Cell Technology, focusing on biopharmaceutical production and stem cell research. She has held leadership roles in various scientific committees and has published over 310 papers.
Currently, Paula is a member of the National Academy of Engineering (USA), of several international advisory committees and has received multiple awards for her contributions to biomanufacturing and biotherapeutics.
Careers
Looking to make a difference in people’s lives?
Why work at ViSync?
Innovate at the forefront of science
Be part of a groundbreaking company addressing some of the most complex challenges in medicine. Work alongside leading experts in science and technology.
Collaborate in a supportive, dynamic team
Work in a culture that values every voice and fosters teamwork. In a young and highly specialized team you can learn, grow, and contribute to cutting-edge science.
Grow your career with impact
Create life-changing therapies while advancing your career. We offer opportunities for growth, leadership, and meaningful contributions to healthcare’s future.
Contact us
Let’s make it happen
Connect with us to learn more about our services and explore how ViSync Technologies can partner with you to develop innovative solutions in cell and gene therapy.
Office
Av. República, Qta. do Marquês
Building Biofarma
2780-157 Oeiras - Portugal